nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABCG2—Fluorouracil—head and neck cancer	0.0529	0.206	CbGbCtD
Nilotinib—CYP2D6—Hydroxyurea—head and neck cancer	0.0471	0.183	CbGbCtD
Nilotinib—ABCG2—Docetaxel—head and neck cancer	0.0404	0.158	CbGbCtD
Nilotinib—CYP2C8—Fluorouracil—head and neck cancer	0.0282	0.11	CbGbCtD
Nilotinib—CYP2C9—Fluorouracil—head and neck cancer	0.0197	0.0767	CbGbCtD
Nilotinib—ABCB1—Vinblastine—head and neck cancer	0.0177	0.0689	CbGbCtD
Nilotinib—CYP2D6—Vinblastine—head and neck cancer	0.0167	0.0649	CbGbCtD
Nilotinib—ABCB1—Docetaxel—head and neck cancer	0.0146	0.0568	CbGbCtD
Nilotinib—CA6—submandibular gland—head and neck cancer	0.0138	0.073	CbGeAlD
Nilotinib—CYP3A4—Vinblastine—head and neck cancer	0.0106	0.0413	CbGbCtD
Nilotinib—CYP3A4—Docetaxel—head and neck cancer	0.00873	0.034	CbGbCtD
Nilotinib—MAPK8—cartilage tissue—head and neck cancer	0.00645	0.0341	CbGeAlD
Nilotinib—CA6—saliva—head and neck cancer	0.00497	0.0263	CbGeAlD
Nilotinib—CA6—ear—head and neck cancer	0.00455	0.024	CbGeAlD
Nilotinib—CA3—ear—head and neck cancer	0.00431	0.0227	CbGeAlD
Nilotinib—MAPK8—exocrine gland—head and neck cancer	0.0035	0.0185	CbGeAlD
Nilotinib—EPHA4—tongue—head and neck cancer	0.00268	0.0142	CbGeAlD
Nilotinib—MAPK8—mouth—head and neck cancer	0.00262	0.0138	CbGeAlD
Nilotinib—CA6—exocrine gland—head and neck cancer	0.00252	0.0133	CbGeAlD
Nilotinib—CA6—hair follicle—head and neck cancer	0.0024	0.0127	CbGeAlD
Nilotinib—MAPK8—neck—head and neck cancer	0.00224	0.0118	CbGeAlD
Nilotinib—MAPK14—hair follicle—head and neck cancer	0.00212	0.0112	CbGeAlD
Nilotinib—CA6—mouth—head and neck cancer	0.00188	0.00993	CbGeAlD
Nilotinib—EPHA4—mouth—head and neck cancer	0.0018	0.00952	CbGeAlD
Nilotinib—CA3—mouth—head and neck cancer	0.00178	0.00941	CbGeAlD
Nilotinib—MAPK14—mouth—head and neck cancer	0.00166	0.00878	CbGeAlD
Nilotinib—MAPK8—connective tissue—head and neck cancer	0.0016	0.00847	CbGeAlD
Nilotinib—FRK—lymphoid tissue—head and neck cancer	0.00154	0.00812	CbGeAlD
Nilotinib—MAPK8—epithelium—head and neck cancer	0.00152	0.00804	CbGeAlD
Nilotinib—CDC42BPB—trachea—head and neck cancer	0.00149	0.00786	CbGeAlD
Nilotinib—BLK—lymphoid tissue—head and neck cancer	0.00148	0.00784	CbGeAlD
Nilotinib—LYN—connective tissue—head and neck cancer	0.00148	0.00782	CbGeAlD
Nilotinib—EPHB2—lymphoid tissue—head and neck cancer	0.00147	0.00775	CbGeAlD
Nilotinib—KIT—exocrine gland—head and neck cancer	0.00146	0.00772	CbGeAlD
Nilotinib—EPHB3—saliva-secreting gland—head and neck cancer	0.00144	0.0076	CbGeAlD
Nilotinib—MAPK14—neck—head and neck cancer	0.00142	0.00751	CbGeAlD
Nilotinib—TIE1—epithelium—head and neck cancer	0.00132	0.00697	CbGeAlD
Nilotinib—CA6—parotid gland—head and neck cancer	0.00131	0.00692	CbGeAlD
Nilotinib—CA6—saliva-secreting gland—head and neck cancer	0.00125	0.00662	CbGeAlD
Nilotinib—CA3—parotid gland—head and neck cancer	0.00124	0.00655	CbGeAlD
Nilotinib—MAPK11—thyroid gland—head and neck cancer	0.00119	0.00627	CbGeAlD
Nilotinib—EPHB2—head—head and neck cancer	0.00118	0.00624	CbGeAlD
Nilotinib—CDC42BPB—thyroid gland—head and neck cancer	0.00118	0.00622	CbGeAlD
Nilotinib—MAPK8—lymphoid tissue—head and neck cancer	0.00117	0.00619	CbGeAlD
Nilotinib—EPHA8—head—head and neck cancer	0.00113	0.00599	CbGeAlD
Nilotinib—EPHA3—thyroid gland—head and neck cancer	0.00112	0.0059	CbGeAlD
Nilotinib—EPHB3—trachea—head and neck cancer	0.00111	0.00587	CbGeAlD
Nilotinib—EPHB4—parotid gland—head and neck cancer	0.0011	0.0058	CbGeAlD
Nilotinib—KIT—mouth—head and neck cancer	0.00109	0.00577	CbGeAlD
Nilotinib—CA3—connective tissue—head and neck cancer	0.00109	0.00576	CbGeAlD
Nilotinib—LYN—lymphoid tissue—head and neck cancer	0.00108	0.00572	CbGeAlD
Nilotinib—EPHA2—parotid gland—head and neck cancer	0.00108	0.00569	CbGeAlD
Nilotinib—MAP4K1—lymphoid tissue—head and neck cancer	0.00107	0.00563	CbGeAlD
Nilotinib—MAPK8—thyroid gland—head and neck cancer	0.00107	0.00563	CbGeAlD
Nilotinib—MAPK11—head—head and neck cancer	0.00105	0.00557	CbGeAlD
Nilotinib—EPHB4—saliva-secreting gland—head and neck cancer	0.00105	0.00555	CbGeAlD
Nilotinib—CDC42BPB—head—head and neck cancer	0.00105	0.00552	CbGeAlD
Nilotinib—EPHA2—saliva-secreting gland—head and neck cancer	0.00103	0.00545	CbGeAlD
Nilotinib—HCK—trachea—head and neck cancer	0.00102	0.00539	CbGeAlD
Nilotinib—MAPK14—connective tissue—head and neck cancer	0.00102	0.00538	CbGeAlD
Nilotinib—EPHB6—parotid gland—head and neck cancer	0.001	0.0053	CbGeAlD
Nilotinib—CA7—trachea—head and neck cancer	0.000999	0.00527	CbGeAlD
Nilotinib—EPHA3—head—head and neck cancer	0.000991	0.00523	CbGeAlD
Nilotinib—MAP4K1—thyroid gland—head and neck cancer	0.000969	0.00511	CbGeAlD
Nilotinib—MAPK14—epithelium—head and neck cancer	0.000968	0.00511	CbGeAlD
Nilotinib—EPHB4—connective tissue—head and neck cancer	0.000966	0.0051	CbGeAlD
Nilotinib—EPHB6—saliva-secreting gland—head and neck cancer	0.000962	0.00508	CbGeAlD
Nilotinib—MAPK8—head—head and neck cancer	0.000945	0.00499	CbGeAlD
Nilotinib—EPHA6—head—head and neck cancer	0.000945	0.00499	CbGeAlD
Nilotinib—KIT—neck—head and neck cancer	0.000934	0.00493	CbGeAlD
Nilotinib—EPHA4—trachea—head and neck cancer	0.000928	0.0049	CbGeAlD
Nilotinib—TEK—connective tissue—head and neck cancer	0.000925	0.00488	CbGeAlD
Nilotinib—TIE1—thyroid gland—head and neck cancer	0.000924	0.00488	CbGeAlD
Nilotinib—EPHB4—epithelium—head and neck cancer	0.000917	0.00484	CbGeAlD
Nilotinib—PDGFRB—neck—head and neck cancer	0.000913	0.00482	CbGeAlD
Nilotinib—EPHA2—epithelium—head and neck cancer	0.0009	0.00475	CbGeAlD
Nilotinib—HCK—lymphoid tissue—head and neck cancer	0.000889	0.00469	CbGeAlD
Nilotinib—BRAF—thyroid gland—head and neck cancer	0.000886	0.00468	CbGeAlD
Nilotinib—TEK—epithelium—head and neck cancer	0.000878	0.00463	CbGeAlD
Nilotinib—LYN—head—head and neck cancer	0.000873	0.00461	CbGeAlD
Nilotinib—CA2—exocrine gland—head and neck cancer	0.000866	0.00457	CbGeAlD
Nilotinib—MAP2K5—parotid gland—head and neck cancer	0.000859	0.00453	CbGeAlD
Nilotinib—LCK—trachea—head and neck cancer	0.000852	0.0045	CbGeAlD
Nilotinib—PDGFRA—connective tissue—head and neck cancer	0.000838	0.00442	CbGeAlD
Nilotinib—BLK—lymph node—head and neck cancer	0.000838	0.00442	CbGeAlD
Nilotinib—CA2—hair follicle—head and neck cancer	0.000826	0.00436	CbGeAlD
Nilotinib—MAP2K5—saliva-secreting gland—head and neck cancer	0.000822	0.00434	CbGeAlD
Nilotinib—TIE1—head—head and neck cancer	0.00082	0.00433	CbGeAlD
Nilotinib—EPHB4—trachea—head and neck cancer	0.000811	0.00428	CbGeAlD
Nilotinib—HCK—thyroid gland—head and neck cancer	0.000808	0.00426	CbGeAlD
Nilotinib—ABL2—thyroid gland—head and neck cancer	0.000803	0.00424	CbGeAlD
Nilotinib—EPHA2—trachea—head and neck cancer	0.000796	0.0042	CbGeAlD
Nilotinib—EPHB3—head—head and neck cancer	0.00078	0.00412	CbGeAlD
Nilotinib—CA12—connective tissue—head and neck cancer	0.000773	0.00408	CbGeAlD
Nilotinib—KIT—parotid gland—head and neck cancer	0.000761	0.00402	CbGeAlD
Nilotinib—MAPK14—lymphoid tissue—head and neck cancer	0.000745	0.00393	CbGeAlD
Nilotinib—PDGFRB—parotid gland—head and neck cancer	0.000743	0.00392	CbGeAlD
Nilotinib—FGR—lymphoid tissue—head and neck cancer	0.000742	0.00392	CbGeAlD
Nilotinib—EPHB6—trachea—head and neck cancer	0.000742	0.00392	CbGeAlD
Nilotinib—MAPK11—lymph node—head and neck cancer	0.000738	0.0039	CbGeAlD
Nilotinib—CSF1R—connective tissue—head and neck cancer	0.000737	0.00389	CbGeAlD
Nilotinib—EPHA4—thyroid gland—head and neck cancer	0.000734	0.00388	CbGeAlD
Nilotinib—CDC42BPB—lymph node—head and neck cancer	0.000732	0.00386	CbGeAlD
Nilotinib—Haemoglobin—Vinblastine—head and neck cancer	0.000732	0.00348	CcSEcCtD
Nilotinib—KIT—saliva-secreting gland—head and neck cancer	0.000729	0.00385	CbGeAlD
Nilotinib—Haemorrhage—Vinblastine—head and neck cancer	0.000728	0.00346	CcSEcCtD
Nilotinib—Blood bilirubin increased—Docetaxel—head and neck cancer	0.000726	0.00345	CcSEcCtD
Nilotinib—CA3—thyroid gland—head and neck cancer	0.000725	0.00383	CbGeAlD
Nilotinib—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000725	0.00345	CcSEcCtD
Nilotinib—Hypoaesthesia—Vinblastine—head and neck cancer	0.000724	0.00344	CcSEcCtD
Nilotinib—Dermatitis bullous—Fluorouracil—head and neck cancer	0.000723	0.00344	CcSEcCtD
Nilotinib—Pharyngitis—Vinblastine—head and neck cancer	0.000723	0.00343	CcSEcCtD
Nilotinib—Hearing impaired—Docetaxel—head and neck cancer	0.000722	0.00343	CcSEcCtD
Nilotinib—Stomatitis—Hydroxyurea—head and neck cancer	0.000721	0.00343	CcSEcCtD
Nilotinib—Bone pain—Docetaxel—head and neck cancer	0.000717	0.00341	CcSEcCtD
Nilotinib—HCK—head—head and neck cancer	0.000717	0.00378	CbGeAlD
Nilotinib—PDGFRB—saliva-secreting gland—head and neck cancer	0.000712	0.00376	CbGeAlD
Nilotinib—Cardiac failure—Fluorouracil—head and neck cancer	0.000708	0.00336	CcSEcCtD
Nilotinib—Lethargy—Fluorouracil—head and neck cancer	0.000705	0.00335	CcSEcCtD
Nilotinib—PDGFRA—trachea—head and neck cancer	0.000703	0.00371	CbGeAlD
Nilotinib—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000699	0.00332	CcSEcCtD
Nilotinib—EPHA3—lymph node—head and neck cancer	0.000694	0.00366	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—head and neck cancer	0.000693	0.00366	CbGeAlD
Nilotinib—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000691	0.00328	CcSEcCtD
Nilotinib—Blood pressure increased—Docetaxel—head and neck cancer	0.000687	0.00326	CcSEcCtD
Nilotinib—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.000687	0.00326	CcSEcCtD
Nilotinib—CA6—head—head and neck cancer	0.000679	0.00359	CbGeAlD
Nilotinib—MAPK14—thyroid gland—head and neck cancer	0.000677	0.00357	CbGeAlD
Nilotinib—TEK—lymphoid tissue—head and neck cancer	0.000676	0.00357	CbGeAlD
Nilotinib—LCK—thyroid gland—head and neck cancer	0.000674	0.00356	CbGeAlD
Nilotinib—FGR—thyroid gland—head and neck cancer	0.000674	0.00356	CbGeAlD
Nilotinib—KIT—connective tissue—head and neck cancer	0.00067	0.00354	CbGeAlD
Nilotinib—CA4—neck—head and neck cancer	0.000668	0.00353	CbGeAlD
Nilotinib—Haemoglobin—Hydroxyurea—head and neck cancer	0.000667	0.00317	CcSEcCtD
Nilotinib—Influenza like illness—Docetaxel—head and neck cancer	0.000667	0.00317	CcSEcCtD
Nilotinib—Haemorrhage—Hydroxyurea—head and neck cancer	0.000664	0.00316	CcSEcCtD
Nilotinib—ABL1—parotid gland—head and neck cancer	0.000662	0.0035	CbGeAlD
Nilotinib—MAPK8—lymph node—head and neck cancer	0.000662	0.0035	CbGeAlD
Nilotinib—Candida infection—Docetaxel—head and neck cancer	0.000656	0.00312	CcSEcCtD
Nilotinib—Skin exfoliation—Docetaxel—head and neck cancer	0.000656	0.00312	CcSEcCtD
Nilotinib—PDGFRB—connective tissue—head and neck cancer	0.000654	0.00345	CbGeAlD
Nilotinib—Fluid retention—Docetaxel—head and neck cancer	0.000652	0.0031	CcSEcCtD
Nilotinib—EPHA4—head—head and neck cancer	0.000651	0.00344	CbGeAlD
Nilotinib—CA12—trachea—head and neck cancer	0.000649	0.00343	CbGeAlD
Nilotinib—CA2—mouth—head and neck cancer	0.000648	0.00342	CbGeAlD
Nilotinib—Alopecia—Vinblastine—head and neck cancer	0.000643	0.00306	CcSEcCtD
Nilotinib—CA3—head—head and neck cancer	0.000643	0.0034	CbGeAlD
Nilotinib—EPHB4—thyroid gland—head and neck cancer	0.000642	0.00339	CbGeAlD
Nilotinib—KIT—epithelium—head and neck cancer	0.000636	0.00336	CbGeAlD
Nilotinib—ABL1—saliva-secreting gland—head and neck cancer	0.000634	0.00335	CbGeAlD
Nilotinib—MAP2K5—trachea—head and neck cancer	0.000634	0.00335	CbGeAlD
Nilotinib—Dry skin—Fluorouracil—head and neck cancer	0.000633	0.00301	CcSEcCtD
Nilotinib—EPHA2—thyroid gland—head and neck cancer	0.000629	0.00332	CbGeAlD
Nilotinib—Neoplasm—Docetaxel—head and neck cancer	0.000621	0.00295	CcSEcCtD
Nilotinib—PDGFRB—epithelium—head and neck cancer	0.000621	0.00328	CbGeAlD
Nilotinib—CSF1R—trachea—head and neck cancer	0.000619	0.00327	CbGeAlD
Nilotinib—Nasopharyngitis—Fluorouracil—head and neck cancer	0.000618	0.00294	CcSEcCtD
Nilotinib—TEK—thyroid gland—head and neck cancer	0.000614	0.00324	CbGeAlD
Nilotinib—PDGFRA—lymphoid tissue—head and neck cancer	0.000613	0.00323	CbGeAlD
Nilotinib—Pulmonary oedema—Docetaxel—head and neck cancer	0.000611	0.00291	CcSEcCtD
Nilotinib—Muscular weakness—Fluorouracil—head and neck cancer	0.000609	0.0029	CcSEcCtD
Nilotinib—Angiopathy—Hydroxyurea—head and neck cancer	0.000602	0.00286	CcSEcCtD
Nilotinib—MAP4K1—lymph node—head and neck cancer	0.000602	0.00318	CbGeAlD
Nilotinib—MAPK14—head—head and neck cancer	0.0006	0.00317	CbGeAlD
Nilotinib—FGR—head—head and neck cancer	0.000598	0.00316	CbGeAlD
Nilotinib—Sepsis—Docetaxel—head and neck cancer	0.000596	0.00283	CcSEcCtD
Nilotinib—Chills—Hydroxyurea—head and neck cancer	0.000596	0.00283	CcSEcCtD
Nilotinib—Eosinophilia—Fluorouracil—head and neck cancer	0.000591	0.00281	CcSEcCtD
Nilotinib—Ill-defined disorder—Vinblastine—head and neck cancer	0.000588	0.00279	CcSEcCtD
Nilotinib—EPHB6—thyroid gland—head and neck cancer	0.000587	0.0031	CbGeAlD
Nilotinib—Alopecia—Hydroxyurea—head and neck cancer	0.000587	0.00279	CcSEcCtD
Nilotinib—Anaemia—Vinblastine—head and neck cancer	0.000586	0.00278	CcSEcCtD
Nilotinib—ABL1—connective tissue—head and neck cancer	0.000583	0.00308	CbGeAlD
Nilotinib—Angina pectoris—Fluorouracil—head and neck cancer	0.000582	0.00276	CcSEcCtD
Nilotinib—Erythema—Hydroxyurea—head and neck cancer	0.000578	0.00275	CcSEcCtD
Nilotinib—TIE1—lymph node—head and neck cancer	0.000574	0.00303	CbGeAlD
Nilotinib—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000573	0.00272	CcSEcCtD
Nilotinib—Malaise—Vinblastine—head and neck cancer	0.000572	0.00272	CcSEcCtD
Nilotinib—Vertigo—Vinblastine—head and neck cancer	0.000569	0.00271	CcSEcCtD
Nilotinib—Leukopenia—Vinblastine—head and neck cancer	0.000567	0.0027	CcSEcCtD
Nilotinib—Pancytopenia—Fluorouracil—head and neck cancer	0.000567	0.00269	CcSEcCtD
Nilotinib—KIT—trachea—head and neck cancer	0.000562	0.00297	CbGeAlD
Nilotinib—EPHA2—head—head and neck cancer	0.000558	0.00295	CbGeAlD
Nilotinib—Deafness—Docetaxel—head and neck cancer	0.000557	0.00265	CcSEcCtD
Nilotinib—PDGFRA—thyroid gland—head and neck cancer	0.000556	0.00294	CbGeAlD
Nilotinib—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000555	0.00264	CcSEcCtD
Nilotinib—CA2—neck—head and neck cancer	0.000554	0.00292	CbGeAlD
Nilotinib—BRAF—lymph node—head and neck cancer	0.00055	0.00291	CbGeAlD
Nilotinib—PDGFRB—trachea—head and neck cancer	0.000549	0.0029	CbGeAlD
Nilotinib—Hypertension—Vinblastine—head and neck cancer	0.000547	0.0026	CcSEcCtD
Nilotinib—EPHB3—lymph node—head and neck cancer	0.000546	0.00288	CbGeAlD
Nilotinib—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000545	0.00259	CcSEcCtD
Nilotinib—TEK—head—head and neck cancer	0.000545	0.00288	CbGeAlD
Nilotinib—CA4—parotid gland—head and neck cancer	0.000544	0.00287	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—head and neck cancer	0.000539	0.00285	CbGeAlD
Nilotinib—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000536	0.00255	CcSEcCtD
Nilotinib—Pneumonia—Fluorouracil—head and neck cancer	0.000535	0.00254	CcSEcCtD
Nilotinib—Anaemia—Hydroxyurea—head and neck cancer	0.000534	0.00254	CcSEcCtD
Nilotinib—Discomfort—Vinblastine—head and neck cancer	0.000533	0.00253	CcSEcCtD
Nilotinib—Infestation NOS—Fluorouracil—head and neck cancer	0.000532	0.00253	CcSEcCtD
Nilotinib—Infestation—Fluorouracil—head and neck cancer	0.000532	0.00253	CcSEcCtD
Nilotinib—Atrial fibrillation—Docetaxel—head and neck cancer	0.000526	0.0025	CcSEcCtD
Nilotinib—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000525	0.00249	CcSEcCtD
Nilotinib—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000522	0.00248	CcSEcCtD
Nilotinib—Myocardial infarction—Fluorouracil—head and neck cancer	0.000522	0.00248	CcSEcCtD
Nilotinib—Dermatitis bullous—Docetaxel—head and neck cancer	0.000522	0.00248	CcSEcCtD
Nilotinib—Malaise—Hydroxyurea—head and neck cancer	0.000521	0.00248	CcSEcCtD
Nilotinib—CA4—saliva-secreting gland—head and neck cancer	0.000521	0.00275	CbGeAlD
Nilotinib—EPHB6—head—head and neck cancer	0.000521	0.00275	CbGeAlD
Nilotinib—Stomatitis—Fluorouracil—head and neck cancer	0.000519	0.00247	CcSEcCtD
Nilotinib—Conjunctivitis—Fluorouracil—head and neck cancer	0.000517	0.00246	CcSEcCtD
Nilotinib—Urinary tract infection—Fluorouracil—head and neck cancer	0.000517	0.00246	CcSEcCtD
Nilotinib—Leukopenia—Hydroxyurea—head and neck cancer	0.000517	0.00246	CcSEcCtD
Nilotinib—Cardiac failure—Docetaxel—head and neck cancer	0.000511	0.00243	CcSEcCtD
Nilotinib—Lethargy—Docetaxel—head and neck cancer	0.000509	0.00242	CcSEcCtD
Nilotinib—Thrombocytopenia—Vinblastine—head and neck cancer	0.000506	0.00241	CcSEcCtD
Nilotinib—Epistaxis—Fluorouracil—head and neck cancer	0.000502	0.00239	CcSEcCtD
Nilotinib—MAP2K5—thyroid gland—head and neck cancer	0.000502	0.00265	CbGeAlD
Nilotinib—HCK—lymph node—head and neck cancer	0.000502	0.00265	CbGeAlD
Nilotinib—Hyponatraemia—Docetaxel—head and neck cancer	0.000501	0.00238	CcSEcCtD
Nilotinib—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000499	0.00237	CcSEcCtD
Nilotinib—Pain in extremity—Docetaxel—head and neck cancer	0.000499	0.00237	CcSEcCtD
Nilotinib—ABL2—lymph node—head and neck cancer	0.000499	0.00263	CbGeAlD
Nilotinib—PDGFRA—head—head and neck cancer	0.000494	0.00261	CbGeAlD
Nilotinib—Anorexia—Vinblastine—head and neck cancer	0.000493	0.00234	CcSEcCtD
Nilotinib—Migraine—Docetaxel—head and neck cancer	0.000491	0.00233	CcSEcCtD
Nilotinib—CSF1R—thyroid gland—head and neck cancer	0.00049	0.00259	CbGeAlD
Nilotinib—KIT—lymphoid tissue—head and neck cancer	0.00049	0.00259	CbGeAlD
Nilotinib—ABL1—trachea—head and neck cancer	0.000489	0.00258	CbGeAlD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000489	0.00232	CcSEcCtD
Nilotinib—Discomfort—Hydroxyurea—head and neck cancer	0.000486	0.00231	CcSEcCtD
Nilotinib—Haemoglobin—Fluorouracil—head and neck cancer	0.00048	0.00228	CcSEcCtD
Nilotinib—Rhinitis—Fluorouracil—head and neck cancer	0.000479	0.00228	CcSEcCtD
Nilotinib—PDGFRB—lymphoid tissue—head and neck cancer	0.000478	0.00252	CbGeAlD
Nilotinib—Haemorrhage—Fluorouracil—head and neck cancer	0.000478	0.00227	CcSEcCtD
Nilotinib—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000476	0.00226	CcSEcCtD
Nilotinib—Pharyngitis—Fluorouracil—head and neck cancer	0.000474	0.00225	CcSEcCtD
Nilotinib—Oedema—Hydroxyurea—head and neck cancer	0.000472	0.00224	CcSEcCtD
Nilotinib—Infection—Hydroxyurea—head and neck cancer	0.000469	0.00223	CcSEcCtD
Nilotinib—Paraesthesia—Vinblastine—head and neck cancer	0.000464	0.00221	CcSEcCtD
Nilotinib—Dehydration—Docetaxel—head and neck cancer	0.000464	0.0022	CcSEcCtD
Nilotinib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000463	0.0022	CcSEcCtD
Nilotinib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000462	0.0022	CcSEcCtD
Nilotinib—Skin disorder—Hydroxyurea—head and neck cancer	0.000458	0.00218	CcSEcCtD
Nilotinib—Dry skin—Docetaxel—head and neck cancer	0.000457	0.00217	CcSEcCtD
Nilotinib—EPHA4—lymph node—head and neck cancer	0.000456	0.00241	CbGeAlD
Nilotinib—CA12—head—head and neck cancer	0.000456	0.0024	CbGeAlD
Nilotinib—Abdominal pain upper—Docetaxel—head and neck cancer	0.000455	0.00216	CcSEcCtD
Nilotinib—CA2—parotid gland—head and neck cancer	0.000451	0.00238	CbGeAlD
Nilotinib—Breast disorder—Docetaxel—head and neck cancer	0.000451	0.00214	CcSEcCtD
Nilotinib—CA3—lymph node—head and neck cancer	0.00045	0.00238	CbGeAlD
Nilotinib—Anorexia—Hydroxyurea—head and neck cancer	0.00045	0.00214	CcSEcCtD
Nilotinib—Decreased appetite—Vinblastine—head and neck cancer	0.00045	0.00214	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000449	0.00213	CcSEcCtD
Nilotinib—CA1—lymphoid tissue—head and neck cancer	0.000448	0.00236	CbGeAlD
Nilotinib—Nasopharyngitis—Docetaxel—head and neck cancer	0.000446	0.00212	CcSEcCtD
Nilotinib—MAP2K5—head—head and neck cancer	0.000445	0.00235	CbGeAlD
Nilotinib—KIT—thyroid gland—head and neck cancer	0.000445	0.00235	CbGeAlD
Nilotinib—Pain—Vinblastine—head and neck cancer	0.000442	0.0021	CcSEcCtD
Nilotinib—Constipation—Vinblastine—head and neck cancer	0.000442	0.0021	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00044	0.00209	CcSEcCtD
Nilotinib—CSF1R—head—head and neck cancer	0.000435	0.00229	CbGeAlD
Nilotinib—PDGFRB—thyroid gland—head and neck cancer	0.000434	0.00229	CbGeAlD
Nilotinib—CA2—saliva-secreting gland—head and neck cancer	0.000432	0.00228	CbGeAlD
Nilotinib—Arrhythmia—Fluorouracil—head and neck cancer	0.000427	0.00203	CcSEcCtD
Nilotinib—ABL1—lymphoid tissue—head and neck cancer	0.000426	0.00225	CbGeAlD
Nilotinib—Feeling abnormal—Vinblastine—head and neck cancer	0.000426	0.00203	CcSEcCtD
Nilotinib—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000423	0.00201	CcSEcCtD
Nilotinib—Alopecia—Fluorouracil—head and neck cancer	0.000422	0.00201	CcSEcCtD
Nilotinib—Dyspnoea—Hydroxyurea—head and neck cancer	0.000421	0.002	CcSEcCtD
Nilotinib—MAPK14—lymph node—head and neck cancer	0.00042	0.00222	CbGeAlD
Nilotinib—Angina pectoris—Docetaxel—head and neck cancer	0.00042	0.002	CcSEcCtD
Nilotinib—FGR—lymph node—head and neck cancer	0.000419	0.00221	CbGeAlD
Nilotinib—LCK—lymph node—head and neck cancer	0.000419	0.00221	CbGeAlD
Nilotinib—ABCG2—parotid gland—head and neck cancer	0.000418	0.00221	CbGeAlD
Nilotinib—Erythema—Fluorouracil—head and neck cancer	0.000416	0.00198	CcSEcCtD
Nilotinib—Dyspepsia—Hydroxyurea—head and neck cancer	0.000415	0.00197	CcSEcCtD
Nilotinib—Decreased appetite—Hydroxyurea—head and neck cancer	0.00041	0.00195	CcSEcCtD
Nilotinib—Pancytopenia—Docetaxel—head and neck cancer	0.000409	0.00195	CcSEcCtD
Nilotinib—Abdominal pain—Vinblastine—head and neck cancer	0.000409	0.00194	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000407	0.00194	CcSEcCtD
Nilotinib—Fatigue—Hydroxyurea—head and neck cancer	0.000407	0.00193	CcSEcCtD
Nilotinib—Constipation—Hydroxyurea—head and neck cancer	0.000403	0.00192	CcSEcCtD
Nilotinib—Pain—Hydroxyurea—head and neck cancer	0.000403	0.00192	CcSEcCtD
Nilotinib—Neutropenia—Docetaxel—head and neck cancer	0.000403	0.00192	CcSEcCtD
Nilotinib—CA4—trachea—head and neck cancer	0.000402	0.00212	CbGeAlD
Nilotinib—ABCG2—saliva-secreting gland—head and neck cancer	0.0004	0.00211	CbGeAlD
Nilotinib—EPHB4—lymph node—head and neck cancer	0.000399	0.0021	CbGeAlD
Nilotinib—CA2—connective tissue—head and neck cancer	0.000397	0.0021	CbGeAlD
Nilotinib—KIT—head—head and neck cancer	0.000395	0.00208	CbGeAlD
Nilotinib—Weight increased—Docetaxel—head and neck cancer	0.000392	0.00186	CcSEcCtD
Nilotinib—Vision blurred—Fluorouracil—head and neck cancer	0.000392	0.00186	CcSEcCtD
Nilotinib—EPHA2—lymph node—head and neck cancer	0.000391	0.00206	CbGeAlD
Nilotinib—Weight decreased—Docetaxel—head and neck cancer	0.00039	0.00185	CcSEcCtD
Nilotinib—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000389	0.00185	CcSEcCtD
Nilotinib—ABL1—thyroid gland—head and neck cancer	0.000387	0.00204	CbGeAlD
Nilotinib—Pneumonia—Docetaxel—head and neck cancer	0.000386	0.00184	CcSEcCtD
Nilotinib—PDGFRB—head—head and neck cancer	0.000385	0.00203	CbGeAlD
Nilotinib—Anaemia—Fluorouracil—head and neck cancer	0.000385	0.00183	CcSEcCtD
Nilotinib—Infestation NOS—Docetaxel—head and neck cancer	0.000384	0.00183	CcSEcCtD
Nilotinib—Infestation—Docetaxel—head and neck cancer	0.000384	0.00183	CcSEcCtD
Nilotinib—TEK—lymph node—head and neck cancer	0.000381	0.00201	CbGeAlD
Nilotinib—Hypersensitivity—Vinblastine—head and neck cancer	0.000381	0.00181	CcSEcCtD
Nilotinib—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000379	0.0018	CcSEcCtD
Nilotinib—Renal failure—Docetaxel—head and neck cancer	0.000378	0.0018	CcSEcCtD
Nilotinib—CA2—epithelium—head and neck cancer	0.000377	0.00199	CbGeAlD
Nilotinib—Myocardial infarction—Docetaxel—head and neck cancer	0.000377	0.00179	CcSEcCtD
Nilotinib—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000377	0.00179	CcSEcCtD
Nilotinib—Jaundice—Docetaxel—head and neck cancer	0.000375	0.00178	CcSEcCtD
Nilotinib—Stomatitis—Docetaxel—head and neck cancer	0.000375	0.00178	CcSEcCtD
Nilotinib—Conjunctivitis—Docetaxel—head and neck cancer	0.000373	0.00178	CcSEcCtD
Nilotinib—Body temperature increased—Hydroxyurea—head and neck cancer	0.000373	0.00177	CcSEcCtD
Nilotinib—Leukopenia—Fluorouracil—head and neck cancer	0.000372	0.00177	CcSEcCtD
Nilotinib—Asthenia—Vinblastine—head and neck cancer	0.000371	0.00176	CcSEcCtD
Nilotinib—EPHB6—lymph node—head and neck cancer	0.000365	0.00192	CbGeAlD
Nilotinib—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000363	0.00173	CcSEcCtD
Nilotinib—Epistaxis—Docetaxel—head and neck cancer	0.000362	0.00172	CcSEcCtD
Nilotinib—CA1—head—head and neck cancer	0.000361	0.00191	CbGeAlD
Nilotinib—Myalgia—Fluorouracil—head and neck cancer	0.000354	0.00168	CcSEcCtD
Nilotinib—Chest pain—Fluorouracil—head and neck cancer	0.000354	0.00168	CcSEcCtD
Nilotinib—Diarrhoea—Vinblastine—head and neck cancer	0.000354	0.00168	CcSEcCtD
Nilotinib—Discomfort—Fluorouracil—head and neck cancer	0.00035	0.00166	CcSEcCtD
Nilotinib—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000348	0.00165	CcSEcCtD
Nilotinib—Haemoglobin—Docetaxel—head and neck cancer	0.000347	0.00165	CcSEcCtD
Nilotinib—Rhinitis—Docetaxel—head and neck cancer	0.000346	0.00164	CcSEcCtD
Nilotinib—PDGFRA—lymph node—head and neck cancer	0.000346	0.00182	CbGeAlD
Nilotinib—Haemorrhage—Docetaxel—head and neck cancer	0.000345	0.00164	CcSEcCtD
Nilotinib—Hepatitis—Docetaxel—head and neck cancer	0.000345	0.00164	CcSEcCtD
Nilotinib—ABL1—head—head and neck cancer	0.000343	0.00181	CbGeAlD
Nilotinib—Hypoaesthesia—Docetaxel—head and neck cancer	0.000343	0.00163	CcSEcCtD
Nilotinib—Confusional state—Fluorouracil—head and neck cancer	0.000342	0.00163	CcSEcCtD
Nilotinib—Pharyngitis—Docetaxel—head and neck cancer	0.000342	0.00163	CcSEcCtD
Nilotinib—Dizziness—Vinblastine—head and neck cancer	0.000342	0.00163	CcSEcCtD
Nilotinib—Urinary tract disorder—Docetaxel—head and neck cancer	0.000341	0.00162	CcSEcCtD
Nilotinib—Oedema peripheral—Docetaxel—head and neck cancer	0.00034	0.00161	CcSEcCtD
Nilotinib—Oedema—Fluorouracil—head and neck cancer	0.00034	0.00161	CcSEcCtD
Nilotinib—Connective tissue disorder—Docetaxel—head and neck cancer	0.000339	0.00161	CcSEcCtD
Nilotinib—Asthenia—Hydroxyurea—head and neck cancer	0.000338	0.00161	CcSEcCtD
Nilotinib—Urethral disorder—Docetaxel—head and neck cancer	0.000338	0.00161	CcSEcCtD
Nilotinib—Infection—Fluorouracil—head and neck cancer	0.000337	0.0016	CcSEcCtD
Nilotinib—CA2—trachea—head and neck cancer	0.000333	0.00176	CbGeAlD
Nilotinib—Nervous system disorder—Fluorouracil—head and neck cancer	0.000333	0.00158	CcSEcCtD
Nilotinib—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000332	0.00158	CcSEcCtD
Nilotinib—Visual impairment—Docetaxel—head and neck cancer	0.000332	0.00158	CcSEcCtD
Nilotinib—Tachycardia—Fluorouracil—head and neck cancer	0.000331	0.00157	CcSEcCtD
Nilotinib—Vomiting—Vinblastine—head and neck cancer	0.000329	0.00156	CcSEcCtD
Nilotinib—Erythema multiforme—Docetaxel—head and neck cancer	0.000326	0.00155	CcSEcCtD
Nilotinib—Headache—Vinblastine—head and neck cancer	0.000324	0.00154	CcSEcCtD
Nilotinib—Anorexia—Fluorouracil—head and neck cancer	0.000324	0.00154	CcSEcCtD
Nilotinib—Diarrhoea—Hydroxyurea—head and neck cancer	0.000323	0.00153	CcSEcCtD
Nilotinib—Eye disorder—Docetaxel—head and neck cancer	0.000322	0.00153	CcSEcCtD
Nilotinib—Flushing—Docetaxel—head and neck cancer	0.00032	0.00152	CcSEcCtD
Nilotinib—Cardiac disorder—Docetaxel—head and neck cancer	0.00032	0.00152	CcSEcCtD
Nilotinib—CA4—thyroid gland—head and neck cancer	0.000318	0.00168	CbGeAlD
Nilotinib—Hypotension—Fluorouracil—head and neck cancer	0.000317	0.00151	CcSEcCtD
Nilotinib—Angiopathy—Docetaxel—head and neck cancer	0.000313	0.00149	CcSEcCtD
Nilotinib—Dizziness—Hydroxyurea—head and neck cancer	0.000312	0.00148	CcSEcCtD
Nilotinib—MAP2K5—lymph node—head and neck cancer	0.000312	0.00165	CbGeAlD
Nilotinib—Immune system disorder—Docetaxel—head and neck cancer	0.000312	0.00148	CcSEcCtD
Nilotinib—Mediastinal disorder—Docetaxel—head and neck cancer	0.000311	0.00148	CcSEcCtD
Nilotinib—Chills—Docetaxel—head and neck cancer	0.00031	0.00147	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000309	0.00147	CcSEcCtD
Nilotinib—Arrhythmia—Docetaxel—head and neck cancer	0.000308	0.00146	CcSEcCtD
Nilotinib—Nausea—Vinblastine—head and neck cancer	0.000307	0.00146	CcSEcCtD
Nilotinib—Insomnia—Fluorouracil—head and neck cancer	0.000307	0.00146	CcSEcCtD
Nilotinib—Paraesthesia—Fluorouracil—head and neck cancer	0.000305	0.00145	CcSEcCtD
Nilotinib—Alopecia—Docetaxel—head and neck cancer	0.000305	0.00145	CcSEcCtD
Nilotinib—CSF1R—lymph node—head and neck cancer	0.000304	0.00161	CbGeAlD
Nilotinib—Dyspnoea—Fluorouracil—head and neck cancer	0.000303	0.00144	CcSEcCtD
Nilotinib—Mental disorder—Docetaxel—head and neck cancer	0.000302	0.00144	CcSEcCtD
Nilotinib—Erythema—Docetaxel—head and neck cancer	0.0003	0.00143	CcSEcCtD
Nilotinib—Malnutrition—Docetaxel—head and neck cancer	0.0003	0.00143	CcSEcCtD
Nilotinib—Vomiting—Hydroxyurea—head and neck cancer	0.0003	0.00143	CcSEcCtD
Nilotinib—Dyspepsia—Fluorouracil—head and neck cancer	0.000299	0.00142	CcSEcCtD
Nilotinib—Rash—Hydroxyurea—head and neck cancer	0.000297	0.00141	CcSEcCtD
Nilotinib—Dermatitis—Hydroxyurea—head and neck cancer	0.000297	0.00141	CcSEcCtD
Nilotinib—Headache—Hydroxyurea—head and neck cancer	0.000296	0.0014	CcSEcCtD
Nilotinib—Decreased appetite—Fluorouracil—head and neck cancer	0.000295	0.0014	CcSEcCtD
Nilotinib—Dysgeusia—Docetaxel—head and neck cancer	0.000294	0.0014	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000293	0.00139	CcSEcCtD
Nilotinib—Back pain—Docetaxel—head and neck cancer	0.00029	0.00138	CcSEcCtD
Nilotinib—Pain—Fluorouracil—head and neck cancer	0.00029	0.00138	CcSEcCtD
Nilotinib—CA2—lymphoid tissue—head and neck cancer	0.00029	0.00153	CbGeAlD
Nilotinib—Muscle spasms—Docetaxel—head and neck cancer	0.000289	0.00137	CcSEcCtD
Nilotinib—CA4—head—head and neck cancer	0.000282	0.00149	CbGeAlD
Nilotinib—Nausea—Hydroxyurea—head and neck cancer	0.00028	0.00133	CcSEcCtD
Nilotinib—Feeling abnormal—Fluorouracil—head and neck cancer	0.00028	0.00133	CcSEcCtD
Nilotinib—Anaemia—Docetaxel—head and neck cancer	0.000278	0.00132	CcSEcCtD
Nilotinib—KIT—lymph node—head and neck cancer	0.000276	0.00146	CbGeAlD
Nilotinib—PDGFRB—lymph node—head and neck cancer	0.00027	0.00142	CbGeAlD
Nilotinib—Urticaria—Fluorouracil—head and neck cancer	0.00027	0.00128	CcSEcCtD
Nilotinib—Syncope—Docetaxel—head and neck cancer	0.000269	0.00128	CcSEcCtD
Nilotinib—Leukopenia—Docetaxel—head and neck cancer	0.000269	0.00128	CcSEcCtD
Nilotinib—Body temperature increased—Fluorouracil—head and neck cancer	0.000268	0.00128	CcSEcCtD
Nilotinib—Palpitations—Docetaxel—head and neck cancer	0.000265	0.00126	CcSEcCtD
Nilotinib—Loss of consciousness—Docetaxel—head and neck cancer	0.000264	0.00125	CcSEcCtD
Nilotinib—CA2—thyroid gland—head and neck cancer	0.000264	0.00139	CbGeAlD
Nilotinib—Cough—Docetaxel—head and neck cancer	0.000262	0.00125	CcSEcCtD
Nilotinib—Hypertension—Docetaxel—head and neck cancer	0.000259	0.00123	CcSEcCtD
Nilotinib—Chest pain—Docetaxel—head and neck cancer	0.000256	0.00121	CcSEcCtD
Nilotinib—Arthralgia—Docetaxel—head and neck cancer	0.000256	0.00121	CcSEcCtD
Nilotinib—Myalgia—Docetaxel—head and neck cancer	0.000256	0.00121	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000254	0.00121	CcSEcCtD
Nilotinib—CA1—lymph node—head and neck cancer	0.000253	0.00133	CbGeAlD
Nilotinib—Hypersensitivity—Fluorouracil—head and neck cancer	0.00025	0.00119	CcSEcCtD
Nilotinib—Dry mouth—Docetaxel—head and neck cancer	0.00025	0.00119	CcSEcCtD
Nilotinib—CYP2B6—lymphoid tissue—head and neck cancer	0.000248	0.00131	CbGeAlD
Nilotinib—Confusional state—Docetaxel—head and neck cancer	0.000247	0.00117	CcSEcCtD
Nilotinib—Oedema—Docetaxel—head and neck cancer	0.000245	0.00116	CcSEcCtD
Nilotinib—ABCG2—thyroid gland—head and neck cancer	0.000244	0.00129	CbGeAlD
Nilotinib—Infection—Docetaxel—head and neck cancer	0.000243	0.00116	CcSEcCtD
Nilotinib—Shock—Docetaxel—head and neck cancer	0.000241	0.00115	CcSEcCtD
Nilotinib—ABL1—lymph node—head and neck cancer	0.000241	0.00127	CbGeAlD
Nilotinib—Nervous system disorder—Docetaxel—head and neck cancer	0.00024	0.00114	CcSEcCtD
Nilotinib—Pruritus—Fluorouracil—head and neck cancer	0.00024	0.00114	CcSEcCtD
Nilotinib—Thrombocytopenia—Docetaxel—head and neck cancer	0.00024	0.00114	CcSEcCtD
Nilotinib—Tachycardia—Docetaxel—head and neck cancer	0.000239	0.00114	CcSEcCtD
Nilotinib—Skin disorder—Docetaxel—head and neck cancer	0.000238	0.00113	CcSEcCtD
Nilotinib—CA2—head—head and neck cancer	0.000234	0.00123	CbGeAlD
Nilotinib—Anorexia—Docetaxel—head and neck cancer	0.000234	0.00111	CcSEcCtD
Nilotinib—Diarrhoea—Fluorouracil—head and neck cancer	0.000232	0.0011	CcSEcCtD
Nilotinib—Hypotension—Docetaxel—head and neck cancer	0.000229	0.00109	CcSEcCtD
Nilotinib—Dizziness—Fluorouracil—head and neck cancer	0.000225	0.00107	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000223	0.00106	CcSEcCtD
Nilotinib—Insomnia—Docetaxel—head and neck cancer	0.000222	0.00105	CcSEcCtD
Nilotinib—Paraesthesia—Docetaxel—head and neck cancer	0.00022	0.00105	CcSEcCtD
Nilotinib—Dyspnoea—Docetaxel—head and neck cancer	0.000218	0.00104	CcSEcCtD
Nilotinib—Vomiting—Fluorouracil—head and neck cancer	0.000216	0.00103	CcSEcCtD
Nilotinib—Dyspepsia—Docetaxel—head and neck cancer	0.000216	0.00103	CcSEcCtD
Nilotinib—Rash—Fluorouracil—head and neck cancer	0.000214	0.00102	CcSEcCtD
Nilotinib—Dermatitis—Fluorouracil—head and neck cancer	0.000214	0.00102	CcSEcCtD
Nilotinib—Decreased appetite—Docetaxel—head and neck cancer	0.000213	0.00101	CcSEcCtD
Nilotinib—Headache—Fluorouracil—head and neck cancer	0.000213	0.00101	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000212	0.00101	CcSEcCtD
Nilotinib—Fatigue—Docetaxel—head and neck cancer	0.000211	0.001	CcSEcCtD
Nilotinib—Pain—Docetaxel—head and neck cancer	0.00021	0.000996	CcSEcCtD
Nilotinib—Constipation—Docetaxel—head and neck cancer	0.00021	0.000996	CcSEcCtD
Nilotinib—Feeling abnormal—Docetaxel—head and neck cancer	0.000202	0.00096	CcSEcCtD
Nilotinib—Nausea—Fluorouracil—head and neck cancer	0.000202	0.000959	CcSEcCtD
Nilotinib—Gastrointestinal pain—Docetaxel—head and neck cancer	0.0002	0.000952	CcSEcCtD
Nilotinib—CYP2B6—head—head and neck cancer	0.0002	0.00105	CbGeAlD
Nilotinib—CA4—lymph node—head and neck cancer	0.000198	0.00104	CbGeAlD
Nilotinib—Abdominal pain—Docetaxel—head and neck cancer	0.000194	0.000921	CcSEcCtD
Nilotinib—Body temperature increased—Docetaxel—head and neck cancer	0.000194	0.000921	CcSEcCtD
Nilotinib—Hypersensitivity—Docetaxel—head and neck cancer	0.000181	0.000858	CcSEcCtD
Nilotinib—Asthenia—Docetaxel—head and neck cancer	0.000176	0.000836	CcSEcCtD
Nilotinib—Pruritus—Docetaxel—head and neck cancer	0.000173	0.000824	CcSEcCtD
Nilotinib—ABCB1—epithelium—head and neck cancer	0.000172	0.000909	CbGeAlD
Nilotinib—Diarrhoea—Docetaxel—head and neck cancer	0.000168	0.000797	CcSEcCtD
Nilotinib—CA2—lymph node—head and neck cancer	0.000164	0.000865	CbGeAlD
Nilotinib—Dizziness—Docetaxel—head and neck cancer	0.000162	0.00077	CcSEcCtD
Nilotinib—Vomiting—Docetaxel—head and neck cancer	0.000156	0.000741	CcSEcCtD
Nilotinib—Rash—Docetaxel—head and neck cancer	0.000155	0.000734	CcSEcCtD
Nilotinib—Dermatitis—Docetaxel—head and neck cancer	0.000154	0.000734	CcSEcCtD
Nilotinib—Headache—Docetaxel—head and neck cancer	0.000154	0.00073	CcSEcCtD
Nilotinib—ABCB1—trachea—head and neck cancer	0.000152	0.000803	CbGeAlD
Nilotinib—ABCG2—lymph node—head and neck cancer	0.000152	0.000801	CbGeAlD
Nilotinib—CYP2D6—head—head and neck cancer	0.000148	0.000784	CbGeAlD
Nilotinib—Nausea—Docetaxel—head and neck cancer	0.000146	0.000692	CcSEcCtD
Nilotinib—ABCB1—lymphoid tissue—head and neck cancer	0.000133	0.0007	CbGeAlD
Nilotinib—ABCB1—thyroid gland—head and neck cancer	0.00012	0.000636	CbGeAlD
Nilotinib—ABCB1—head—head and neck cancer	0.000107	0.000564	CbGeAlD
Nilotinib—ABCB1—lymph node—head and neck cancer	7.48e-05	0.000395	CbGeAlD
Nilotinib—MAPK11—Signaling Pathways—CCND1—head and neck cancer	8.47e-06	2.46e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HRAS—head and neck cancer	8.39e-06	2.44e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCND1—head and neck cancer	8.39e-06	2.44e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GPX1—head and neck cancer	8.34e-06	2.43e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MAPK1—head and neck cancer	8.34e-06	2.43e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—head and neck cancer	8.34e-06	2.43e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MAPK3—head and neck cancer	8.33e-06	2.42e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MAPK3—head and neck cancer	8.3e-06	2.42e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—head and neck cancer	8.29e-06	2.41e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP1A1—head and neck cancer	8.26e-06	2.4e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—head and neck cancer	8.26e-06	2.4e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HRAS—head and neck cancer	8.25e-06	2.4e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AKT1—head and neck cancer	8.24e-06	2.4e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PTEN—head and neck cancer	8.17e-06	2.38e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PIK3CA—head and neck cancer	8.15e-06	2.37e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PIK3CA—head and neck cancer	8.15e-06	2.37e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	8.14e-06	2.37e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—MAPK3—head and neck cancer	8.13e-06	2.37e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MAPK1—head and neck cancer	8.1e-06	2.36e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—head and neck cancer	8.1e-06	2.36e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PTEN—head and neck cancer	8.09e-06	2.36e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MAPK3—head and neck cancer	8.09e-06	2.36e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—STAT3—head and neck cancer	8.07e-06	2.35e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—PIK3CA—head and neck cancer	8.04e-06	2.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—STAT3—head and neck cancer	8.02e-06	2.34e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NAT2—head and neck cancer	8.01e-06	2.33e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MAPK1—head and neck cancer	7.93e-06	2.31e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—head and neck cancer	7.93e-06	2.31e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AKT1—head and neck cancer	7.9e-06	2.3e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MAPK1—head and neck cancer	7.9e-06	2.3e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—head and neck cancer	7.9e-06	2.3e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—head and neck cancer	7.89e-06	2.3e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—head and neck cancer	7.83e-06	2.28e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—PTEN—head and neck cancer	7.8e-06	2.27e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOTCH1—head and neck cancer	7.79e-06	2.27e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—MAPK1—head and neck cancer	7.74e-06	2.25e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—head and neck cancer	7.73e-06	2.25e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—AKT1—head and neck cancer	7.72e-06	2.25e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MAPK3—head and neck cancer	7.71e-06	2.24e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MAPK1—head and neck cancer	7.7e-06	2.24e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—head and neck cancer	7.7e-06	2.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MAPK3—head and neck cancer	7.67e-06	2.23e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MAPK3—head and neck cancer	7.66e-06	2.23e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCND1—head and neck cancer	7.63e-06	2.22e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PIK3CA—head and neck cancer	7.61e-06	2.21e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.6e-06	2.21e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AKT1—head and neck cancer	7.58e-06	2.21e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—HRAS—head and neck cancer	7.54e-06	2.2e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TYMS—head and neck cancer	7.46e-06	2.17e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—HRAS—head and neck cancer	7.44e-06	2.16e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PIK3CA—head and neck cancer	7.42e-06	2.16e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—head and neck cancer	7.41e-06	2.16e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—AKT1—head and neck cancer	7.41e-06	2.16e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—head and neck cancer	7.38e-06	2.15e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTM1—head and neck cancer	7.37e-06	2.15e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PTEN—head and neck cancer	7.37e-06	2.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MAPK1—head and neck cancer	7.33e-06	2.13e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—head and neck cancer	7.33e-06	2.13e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—head and neck cancer	7.31e-06	2.13e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—STAT3—head and neck cancer	7.31e-06	2.13e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MAPK1—head and neck cancer	7.29e-06	2.12e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—head and neck cancer	7.29e-06	2.12e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—AKT1—head and neck cancer	7.28e-06	2.12e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—AKT1—head and neck cancer	7.24e-06	2.11e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—STAT3—head and neck cancer	7.24e-06	2.11e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PIK3CA—head and neck cancer	7.23e-06	2.11e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCND1—head and neck cancer	7.23e-06	2.1e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTEN—head and neck cancer	7.2e-06	2.1e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GPX1—head and neck cancer	7.06e-06	2.06e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—head and neck cancer	7.04e-06	2.05e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—DPYD—head and neck cancer	7.03e-06	2.05e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PIK3CA—head and neck cancer	7.03e-06	2.05e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—head and neck cancer	7e-06	2.04e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP1A1—head and neck cancer	6.99e-06	2.03e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK3—head and neck cancer	6.98e-06	2.03e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—STAT3—head and neck cancer	6.97e-06	2.03e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTEN—head and neck cancer	6.97e-06	2.03e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK3—head and neck cancer	6.92e-06	2.01e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTEN—head and neck cancer	6.88e-06	2e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PIK3CA—head and neck cancer	6.88e-06	2e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—head and neck cancer	6.87e-06	2e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PIK3CA—head and neck cancer	6.86e-06	2e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—PIK3CA—head and neck cancer	6.71e-06	1.95e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—head and neck cancer	6.7e-06	1.95e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—head and neck cancer	6.69e-06	1.95e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PIK3CA—head and neck cancer	6.68e-06	1.94e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—head and neck cancer	6.68e-06	1.94e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—YAP1—head and neck cancer	6.67e-06	1.94e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK3—head and neck cancer	6.66e-06	1.94e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—head and neck cancer	6.66e-06	1.94e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—head and neck cancer	6.66e-06	1.94e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—head and neck cancer	6.65e-06	1.94e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—head and neck cancer	6.65e-06	1.94e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK1—head and neck cancer	6.64e-06	1.93e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—head and neck cancer	6.64e-06	1.93e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.63e-06	1.93e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—head and neck cancer	6.59e-06	1.92e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK1—head and neck cancer	6.58e-06	1.92e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—head and neck cancer	6.58e-06	1.92e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—head and neck cancer	6.57e-06	1.91e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—head and neck cancer	6.54e-06	1.9e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—head and neck cancer	6.51e-06	1.89e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—head and neck cancer	6.5e-06	1.89e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TYMS—head and neck cancer	6.5e-06	1.89e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—head and neck cancer	6.44e-06	1.87e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTM1—head and neck cancer	6.42e-06	1.87e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—head and neck cancer	6.37e-06	1.86e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—head and neck cancer	6.36e-06	1.85e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—head and neck cancer	6.36e-06	1.85e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—head and neck cancer	6.34e-06	1.85e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK1—head and neck cancer	6.34e-06	1.85e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—head and neck cancer	6.34e-06	1.85e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—head and neck cancer	6.33e-06	1.84e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—head and neck cancer	6.3e-06	1.83e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK3—head and neck cancer	6.3e-06	1.83e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—head and neck cancer	6.28e-06	1.83e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—head and neck cancer	6.24e-06	1.82e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—head and neck cancer	6.22e-06	1.81e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—head and neck cancer	6.21e-06	1.81e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—head and neck cancer	6.2e-06	1.8e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—head and neck cancer	6.18e-06	1.8e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK3—head and neck cancer	6.15e-06	1.79e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GPX1—head and neck cancer	6.15e-06	1.79e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—head and neck cancer	6.15e-06	1.79e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TYMS—head and neck cancer	6.12e-06	1.78e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP1A1—head and neck cancer	6.09e-06	1.77e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TYMS—head and neck cancer	6.07e-06	1.77e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—head and neck cancer	6.06e-06	1.76e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTM1—head and neck cancer	6.05e-06	1.76e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—head and neck cancer	6.04e-06	1.76e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTM1—head and neck cancer	6e-06	1.75e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK1—head and neck cancer	5.99e-06	1.74e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—head and neck cancer	5.99e-06	1.74e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK3—head and neck cancer	5.96e-06	1.73e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—head and neck cancer	5.91e-06	1.72e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—head and neck cancer	5.89e-06	1.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—head and neck cancer	5.86e-06	1.7e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK1—head and neck cancer	5.85e-06	1.7e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—head and neck cancer	5.85e-06	1.7e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—head and neck cancer	5.84e-06	1.7e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—head and neck cancer	5.83e-06	1.7e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GPX1—head and neck cancer	5.8e-06	1.69e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—head and neck cancer	5.76e-06	1.68e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GPX1—head and neck cancer	5.75e-06	1.67e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.74e-06	1.67e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—head and neck cancer	5.74e-06	1.67e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP1A1—head and neck cancer	5.74e-06	1.67e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—head and neck cancer	5.71e-06	1.66e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP1A1—head and neck cancer	5.69e-06	1.66e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—head and neck cancer	5.68e-06	1.65e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK1—head and neck cancer	5.67e-06	1.65e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—head and neck cancer	5.67e-06	1.65e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—head and neck cancer	5.62e-06	1.64e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—head and neck cancer	5.62e-06	1.64e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—head and neck cancer	5.6e-06	1.63e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—head and neck cancer	5.58e-06	1.62e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—head and neck cancer	5.56e-06	1.62e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—head and neck cancer	5.52e-06	1.61e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—head and neck cancer	5.5e-06	1.6e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—head and neck cancer	5.5e-06	1.6e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—head and neck cancer	5.48e-06	1.6e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—head and neck cancer	5.46e-06	1.59e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK3—head and neck cancer	5.37e-06	1.56e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—head and neck cancer	5.36e-06	1.56e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—head and neck cancer	5.33e-06	1.55e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—head and neck cancer	5.28e-06	1.54e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—head and neck cancer	5.27e-06	1.53e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK3—head and neck cancer	5.26e-06	1.53e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—head and neck cancer	5.22e-06	1.52e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—head and neck cancer	5.22e-06	1.52e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—head and neck cancer	5.2e-06	1.51e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—head and neck cancer	5.2e-06	1.51e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—head and neck cancer	5.17e-06	1.51e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—head and neck cancer	5.17e-06	1.5e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK1—head and neck cancer	5.11e-06	1.49e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—head and neck cancer	5.11e-06	1.49e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—head and neck cancer	5.09e-06	1.48e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—head and neck cancer	5.08e-06	1.48e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—head and neck cancer	5.04e-06	1.47e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—head and neck cancer	5.03e-06	1.46e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK1—head and neck cancer	5e-06	1.46e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—head and neck cancer	5e-06	1.46e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK3—head and neck cancer	4.98e-06	1.45e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—head and neck cancer	4.92e-06	1.43e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—head and neck cancer	4.91e-06	1.43e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—head and neck cancer	4.86e-06	1.41e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—head and neck cancer	4.81e-06	1.4e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—head and neck cancer	4.76e-06	1.39e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK1—head and neck cancer	4.74e-06	1.38e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—head and neck cancer	4.74e-06	1.38e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—head and neck cancer	4.71e-06	1.37e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—head and neck cancer	4.7e-06	1.37e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.67e-06	1.36e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—head and neck cancer	4.66e-06	1.36e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—head and neck cancer	4.55e-06	1.33e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—head and neck cancer	4.55e-06	1.32e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—head and neck cancer	4.51e-06	1.31e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—head and neck cancer	4.49e-06	1.31e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—head and neck cancer	4.43e-06	1.29e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—head and neck cancer	4.34e-06	1.26e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK3—head and neck cancer	4.31e-06	1.25e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—head and neck cancer	4.29e-06	1.25e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—head and neck cancer	4.28e-06	1.25e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—head and neck cancer	4.25e-06	1.24e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—head and neck cancer	4.2e-06	1.22e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—head and neck cancer	4.16e-06	1.21e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—head and neck cancer	4.15e-06	1.21e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—head and neck cancer	4.12e-06	1.2e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—head and neck cancer	4.11e-06	1.2e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—head and neck cancer	4.1e-06	1.19e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK1—head and neck cancer	4.1e-06	1.19e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—head and neck cancer	4.1e-06	1.19e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—head and neck cancer	4.02e-06	1.17e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—head and neck cancer	4.02e-06	1.17e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TYMS—head and neck cancer	4e-06	1.17e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—head and neck cancer	3.98e-06	1.16e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—head and neck cancer	3.97e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTM1—head and neck cancer	3.96e-06	1.15e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—head and neck cancer	3.81e-06	1.11e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GPX1—head and neck cancer	3.79e-06	1.1e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	3.75e-06	1.09e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—head and neck cancer	3.63e-06	1.06e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—head and neck cancer	3.62e-06	1.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—head and neck cancer	3.62e-06	1.05e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—head and neck cancer	3.56e-06	1.04e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—head and neck cancer	3.55e-06	1.03e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—head and neck cancer	3.44e-06	1e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—head and neck cancer	3.41e-06	9.93e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—head and neck cancer	3.38e-06	9.85e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—head and neck cancer	3.37e-06	9.8e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—head and neck cancer	3.36e-06	9.78e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—head and neck cancer	3.29e-06	9.58e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—head and neck cancer	3.16e-06	9.19e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—head and neck cancer	3.02e-06	8.79e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—head and neck cancer	2.98e-06	8.66e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—head and neck cancer	2.95e-06	8.59e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—head and neck cancer	2.91e-06	8.46e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—head and neck cancer	2.56e-06	7.44e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—head and neck cancer	2.47e-06	7.18e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—head and neck cancer	2.23e-06	6.49e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—head and neck cancer	2.23e-06	6.49e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—head and neck cancer	2.1e-06	6.11e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—head and neck cancer	2.09e-06	6.08e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—head and neck cancer	2.08e-06	6.06e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—head and neck cancer	1.95e-06	5.66e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—head and neck cancer	1.82e-06	5.3e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—head and neck cancer	1.72e-06	4.99e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—head and neck cancer	1.7e-06	4.95e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.37e-06	4e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—head and neck cancer	1.12e-06	3.26e-06	CbGpPWpGaD
